spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

ERT Continues to Drive Innovation in Virtualization for Respiratory Clinical Trials

ERT

Partnership with Inofab Health keeps respiratory trials on track and ensures patient safety during and after COVID-19



PHILADELPHIA – June 25, 2020 – ERT, the global leader in clinical endpoints data collection, today announced a strategic partnership with Inofab Health, a healthcare technology company designing and developing ultrasonic spirometry technology for in-clinic and at-home use. Through the partnership, ERT expands its portfolio of innovative virtual trial solutions to give clinical trial sponsors and contract research organizations (CROs) multiple options for continuing their life-saving research throughout the pandemic and beyond.

Sponsors are looking for reliable data collection methods that enable the continuation of important clinical trials and ensure the safety of clinical trial patients, without requiring them to attend investigative site appointments. ERT is meeting this need with a suite of innovative virtual trial solutions that capture high-quality data from the comfort of patients’ homes.

“We chose to partner with Inofab based on their proven capabilities in meeting respiratory patients’ healthcare needs and their award-winning ultrasonic spirometer, Spirohome,” said Achim Schülke, Executive Vice President of Respiratory Solutions at ERT. “This partnership enables ERT to further drive innovation in trial virtualization and supports our commitment to offering the best range of trial continuity options, specifically for sponsors developing new respiratory disease treatments.”

Since patients with lung disease are at higher risk for developing more serious complications from the COVID-19 illness, many are likely to avoid clinics or investigative sites to minimize their exposure risk. Together, ERT and Inofab will continue to develop patient-friendly, easy to use solutions enabling at-home, patient-administered testing of the lung, supporting patient comfort and safety while ensuring high-quality data collection to keep respiratory trials on track.

“We’re pleased to partner with ERT and to leverage their extensive experience in delivering the important safety and efficacy data sponsors need when developing new respiratory treatments,” said Kerem Yasar, Chief Technology Officer and Co-Founder of Inofab Health. “Spirohome plays a critical role for endpoint data collection and we’re excited to work with ERT in delivering virtual trial solutions that help clinical trial sponsors continue developing new treatments for the millions of patients living with respiratory disease.”

For more information on ERT’s suite of virtual trial solutions, visit virtualtrials.ert.com.
phone +1 800 961 5004
email eresearch@ert.com
web www.ert.com
email 1818 Market Street, Suite 1000, Philadelphia, PA 19103
 
Print this page
Send to a friend
   
spacer
News and Press Releases

ROUSSELOT INTRODUCES X-PURE® GelMA FOR TRANSLATIONAL MEDICINE

Irving, United States [03 June 2020] — Rousselot, a Darling Ingredients brand and the global leader of collagen-based solutions, takes on the digital challenge and introduces X-Pure® GelMA at Bio Digital 2020. The first GMP-ready range of gelatin methacryloyl (GelMA) biomaterials suitable for preclinical and clinical applications, X-Pure® GelMA is part of the X-Pure portfolio of ultra-pure gelatins and collagens, suitable for use as biomaterials in 3D bioprinting, tissue engineering, and regenerative medicine.
More info >>


White Papers

CRSF Label - Child-Resistant Blister Packs With Booklet Label

Faubel & Co. Nachfolger GmbH

This case study explains how Faubel was commissioned by a leading global pharmaceutical company to develop a label for an aluminum blister pack with 14 cavities, which was used as part of a multinational clinical trial. This label was intended to both protect infants from erroneous ingestion and facilitate use by seniors.
More info >>

Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement